We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF
XBI

781 hedge funds and large institutions have $9.75B invested in State Street SPDR S&P Biotech ETF in 2024 Q1 according to their latest regulatory filings, with 130 funds opening new positions, 258 increasing their positions, 231 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 130 | Existing positions closed: 83

29% more capital invested

Capital invested by funds: $7.54B → $9.75B (+$2.21B)

26.99% more ownership

Funds ownership: 103.83% → 130.81% (+27%)

12% more repeat investments, than reductions

Existing positions increased: 258 | Existing positions reduced: 231

5% more funds holding

Funds holding: 745 → 781 (+36)

0% more funds holding in top 10

Funds holding in top 10: 23 → 23 (0)

43% less call options, than puts

Call options by funds: $2.25B | Put options by funds: $3.97B

Holders
781
Holders Change
+36
Holders Change %
+4.83%
% of All Funds
11.22%
Holding in Top 10
23
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.33%
New
130
Increased
258
Reduced
231
Closed
83
Calls
$2.25B
Puts
$3.97B
Net Calls
-$1.72B
Net Calls Change
-$470M

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$437M
2
Bank of America
Bank of America
North Carolina
+$382M
3
JP Morgan Chase
JP Morgan Chase
New York
+$348M
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$274M
5
Morgan Stanley
Morgan Stanley
New York
+$180M

Top Sellers

Rank Fund Capital Flow
1
MCM
Moore Capital Management
New York
-$146M
2
Twin Tree Management
Twin Tree Management
Texas
-$65.3M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
UBS Group
UBS Group
Switzerland
-$56.6M
5
Squarepoint
Squarepoint
New York
-$54.6M

XBI Hedge Fund Activity: Q1 2024 in Review

781 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2024, worth a combined $9.75B — up 29% from $7.54B a quarter earlier.

Buyers outnumbered sellers: 130 funds opened new XBI positions and 83 closed out — a net gain of 47 holders — while 258 added to existing stakes and 231 trimmed.

The largest buyer was Citigroup, adding an estimated $437M. The largest seller was Moore Capital Management, cutting an estimated $146M.

  • 781 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2024, up from 745 in Q4 2023.
  • Funds reported $9.75B of State Street SPDR S&P Biotech ETF stock for Q1 2024, up 29% quarter-over-quarter.
  • 130 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2024 and 83 closed out, a net change of +47 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q1 2024 was Citigroup, an estimated $437M added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q1 2024 was Moore Capital Management, an estimated $146M sold.

Based on aggregated 13F filings for Q1 2024.